Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor

Medicine and Dentistry

• Fibroblast 41%
• Mammalian Target of Rapamycin 33%
• Programmed Cell Death 25%
• In Vitro 8%
• Combination Therapy 8%
• Angiogenesis 8%
• Ex Vivo 8%
• Growth Disorder 8%
• Wortmannin 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Mammalian Target of Rapamycin Inhibitor 16%
• Rapamycin 16%
• Combination Therapy 8%